These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27493845)

  • 1. Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
    Saif MW; Agarwal A; Hellinger J; Park DJ; Volkmann E
    Cureus; 2016 Jun; 8(6):e663. PubMed ID: 27493845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome and concurrent hand foot syndrome during treatment with capecitabine: A case report.
    Ahn HR; Lee SK; Youn HJ; Yun SK; Lee IJ
    World J Clin Cases; 2021 Jun; 9(17):4279-4284. PubMed ID: 34141791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
    Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
    Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
    Trindade F; Haro R; Fariña MC; Requena L
    Am J Dermatopathol; 2008 Apr; 30(2):172-3. PubMed ID: 18360124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report.
    Inokuchi M; Ishikawa S; Furukawa H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
    Oncol Lett; 2014 Feb; 7(2):444-448. PubMed ID: 24396465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
    Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
    Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
    Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine-induced hand-foot syndrome does not emerge in the complex regional pain syndrome-affected limb: A case report.
    Inoue R; Abe H; Konishi M; Tsuchida R; Edamura T; Sumitani M
    Mol Clin Oncol; 2021 Dec; 15(6):254. PubMed ID: 34671472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
    Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient.
    Whorton AE; Razzak AN; Jha P
    Cureus; 2022 Jul; 14(7):e26891. PubMed ID: 35978746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia.
    Dawood T; Zahir MN; Afzal M; Rashid YA
    Cureus; 2021 Jun; 13(6):e15519. PubMed ID: 34268045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
    Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
    Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.